" HR+ P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer (HR+ Cohort)"
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
October 4, 2022
End Date
October 4, 2025
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
October 4, 2022
End Date
October 4, 2025